Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Rab 34 CRISPR/Cas9 KO Plasmid (h): sc-406606
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Rab 34 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Rab 34 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Rab 34 Antibody (C-5): sc-376710
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rab 34 CRISPR/Cas9 KO Plasmid (h) | sc-406606 | 20 µg | $397.00 |
Overview
RAB34 encodes Rab 34, a small GTPase of the Rab family that regulates intracellular membrane trafficking, with reported roles in Golgi and endosomal dynamics, lysosome positioning, and phagosome maturation. Through cycling between GTP- and GDP-bound states, Rab 34 helps coordinate vesicle transport, organelle tethering, and cargo sorting that influence receptor turnover and signaling outputs. Dysregulation of Rab-mediated trafficking can perturb autophagy–lysosome function and membrane homeostasis, processes frequently examined in studies of cancer cell behavior, neurodegeneration, and host–pathogen interactions. RAB34 is therefore a useful node for dissecting vesicular transport pathways and their impact on cellular physiology.
Rab 34 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RAB34 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RAB34 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RAB34 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Rab 34 protein expression.
This CRISPR knockout system enables efficient generation of RAB34-deficient cell models for investigation of Rab 34 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RAB34 exon(s) critical for Rab 34 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RAB34 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Rab 34 CRISPR/Cas9 KO Plasmid (h) and Rab 34 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RAB34 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Rab 34 HDR Plasmid (h) and Rab 34 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RAB34 homology arms to support homology-directed repair at defined RAB34 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.